A Phase 3 Study to Evaluate the Efficacy of JY09 Compared With Placebo in T2DM Patients

A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 270 participants.

Also called NCT06254014

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 270 participants (enrolled count) (from the registry)
Sponsor
Beijing Dongfang Biotech Co., Ltd. (from the registry)
Registry
  • NCT NCT06254014
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT06254014. Randomized; quadruple masking; primary purpose treatment. Start 2024-07-10 (actual); primary completion 2026-05-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Phase 3 Study to Evaluate the Efficacy of JY09 Compared With Placebo in T2DM Patients
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
Exendin-4 Fc fusion protein injection
Intervention (Drug)
Exendin-4 Fc fusion protein injection
Intervention (Drug)
Placebo
Lead sponsor
Beijing Dongfang Biotech Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct06254014
Content hash
64d8ef9bbf860e14379dc4b1f466ba6a0488afd81d55f22aad48851a008cce41